CD226 and type 1 diabetes mellitus: Further characterization of the downstream effects of CD8+ T cell activation in the CD226 KO NOD model via ex vivo analysis of cytokines, perforin, and granzymes (55) or in vitro analysis of antigen-specific proliferation and β cell killing (56) are currently underway to further understand the extent to which these mechanisms translate to human type 1 diabetes.